Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

NCT07334431 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastric (Stomach) Cancer
GEJ Adenocarcinoma
HER2-positive Gastric Cancer
First-line Therapy
Fruquintinib

Interventions

DRUG: fruquintinib＋trastuzumab + XELOX

Sponsor

Henan Cancer Hospital